Trial Profile
Characteristics of patients with epistaxis treated with rivaroxaban compared to those with phenprocoumon.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Phenprocoumon (Primary) ; Rivaroxaban (Primary)
- Indications Epistaxis
- Focus Therapeutic Use
- 12 Oct 2018 New trial record